Curcumin and Notoginsenoside Ft1, acting as a natural TGR5 agonist and an intestinal FXR inhibitor, exerts a dual effect that alleviates metabolic disorders by activating TGR5 while simultaneously suppressing FXR (199, 200). The gene discussed is GPBAR1; the disease is metabolic disease.